查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1809921

经颈静脉肝内门体分流术 (TIPS) 市场（按产品类型、手术类型、最终用户和应用）- 全球预测，2025-2030 年

Transjugular Intrahepatic Portosystemic Shunt Market by Product Type, Procedure Type, End User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年经颈静脉肝内门体分流术 (TIPS) 市值为 1.026 亿美元，预计 2025 年将成长至 1.0683 亿美元，复合年增长率为 4.27%，到 2030 年将达到 1.3188 亿美元。

主要市场统计数据
基准年2024年 1.026亿美元
预计2025年 1.0683亿美元
预测年份 2030 1.3188亿美元
复合年增长率（%） 4.27%

无与伦比的临床和技术创新为经颈静脉肝内门体分流术 (TIPS) 治疗的未来铺平了道路

经颈静脉肝内门体分流术 (TIPS) 是一项突破性的介入手术，旨在透过在肝臟内建立连接门静脉和体静脉循环的通道来缓解门静脉高压。这种微创方法自诞生以来取得了显着进展，已从一项实验通讯协定发展成为治疗顽固性腹水、静脉曲张出血、布加综合征和肝肾综合征等併发症的标准治疗方法。多年来，支架设计、影像引导和技术的不断改进，提高了 TIPSS 的安全性和临床有效性，推动了其在心血管和肝病领域的应用。

引领创新进步，精准有效塑造经颈静脉肝内门体分流术 (TIPS) 设置

由于器械工程和操作指导方面的突破性进展，经颈静脉肝内门体分流术 (TIPS) 治疗领域正在发生重大变革时期。现代覆膜支架技术显着减少了支架内血管再阻塞和分流功能障碍，从而提高了门静脉高压症患者的通畅率并改善了患者的长期预后。同时，在成本和操作灵活性至关重要的情况下，裸金属支架的改进仍发挥补充作用。

全面评估美国新关税对经颈静脉肝内门体分流术 (TIPS) 设备的可用性和可负担性的影响。

2025年，美国对进口医疗设备征收的新关税生效，凸显了TIPSS组件的经济效益。进口支架及套件的附加税导致专用移植物、球囊导管和扩张器的土地价格逐步上涨，给医院采购预算带来了上行压力。随着供应商重新评估其定价结构，医疗保健提供者正在评估替代筹资策略的成本效益。

揭示关键的细分观点，揭示经颈静脉肝内门体分流术 (TIPS) 市场分析和采用动态中的不同途径

仔细研究产品类型细分，我们发现，儘管长期以来临床上支架比附件更受青睐，但由于其在缓解分流功能障碍方面的卓越性能，人们已明显转向覆膜支架。在覆膜支架类别中，製造商正透过专有的覆膜涂层和混合金属合金来平衡柔韧性和径向强度，从而实现差异化。同时，球囊扩张器和导引鞘套等配件也在不断发展，融入了低摩擦聚合物和增强的外形设计，以简化器械输送。

了解影响美洲、欧洲、中东、非洲和亚太地区经颈静脉肝内门体分流术 (TIPS) 普及的区域动态和采用驱动因素。

经颈静脉肝内门体分流术 (TIPS) 疗法的采用和发展在很大程度上受到区域因素的影响。在北美和南美，强大的报销框架和高昂的医疗支出创造了有利于新支架技术快速整合的环境。大都会圈的卓越中心正在带头进行临床试验，而区域和社区医院正在采用可扩展的程序平台来扩大患者获得治疗的机会。欧洲、中东和非洲各地不同的监管途径和报销计划需要设备製造商和区域经销商之间建立战略合作伙伴关係。虽然西欧通常作为实践模式的基准，但中东和非洲的新兴市场对介入放射学投资表现出越来越浓厚的兴趣。许多政府正在推出培训计划和官民合作关係，以建立当地专业知识和基础设施。

2025 年经颈静脉肝内门体分流术 (TIPS) 市场参与企业的策略创新、合作伙伴关係和竞争策略亮点

经子宫颈肝内滤过性肝动脉分流术市场的主要相关人员正在采取各种策略倡议，以增强其竞争地位。现有的医疗设备製造商正在大力投资研究合作和临床合作，以改善植入生物材料和输送系统。此类合作不仅加速了实验室研究成果向商业性产品的转化，也加强了与指导手术标准化的关键意见领袖的关係。

实施可行的策略指令，以提高经颈静脉肝内门体分流术 (TIPS) 解决方案的临床效果和市场渗透率

为了抓住新兴机会并应对TIPSS领域的营运挑战，产业领导者应优先对临床医生教育和手术模拟计画进行有针对性的投资。透过培养对先进支架置入技术和影像整合的熟练，医疗中心可以降低併发症发生率并改善患者预后。此外，与肝病学会和放射学会建立合作伙伴关係，可就最佳实践达成共识，并促进其在不同医疗机构的广泛应用。

采用严格的混合调查方法，对经颈静脉肝内门体分流术 (TIPS) 市场动态进行可靠且公正的洞察

本分析采用了严格的混合方法框架，其特点是整合了原始研究和二手资料。原始资料是透过与来自多个地区的介入放射科医生、肝病科医生、采购人员和监管事务专家进行深入访谈收集的。这些见解也透过查阅二手资料（包括同行评审日誌、设备註册资讯、临床试验资料库和公开的监管文件）进行了补充。

综合关键发现以确定经颈静脉肝内门体分流术 (TIPS) 技术和临床应用的未来发展轨迹

临床创新、不断变化的监管格局以及供应链的调整交织在一起，共同构成了经颈静脉肝内门体分流术 (TIPS) 的动态格局。涂层支架材料、影像处理化输送系统以及远端患者监护方面的突破性进展，共同改善了治疗效果，重塑了治疗模式。同时，不断变化的关税结构和区域报销细则迫使相关人员优化製造地并完善打入市场策略。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 全球非酒精性脂肪性肝炎的盛行率不断上升，推动了对 TIPS 手术的需求
  • ePTFE覆膜支架技术创新提升TIPS的长期通畅率
  • 整合影像引导导航系统以提高 TIPS 置放的准确性
  • 引进远端医疗平台，用于远距监测TIPS患者的术后状况
  • 新型可生物降解支架获监理机关核准，为TIPS市场带来更多机会
  • 新兴市场医疗保健投资的增加推动了TIPS干预措施的采用
  • 支援联合TIPS和门静脉栓塞术的混合手术室平台
  • 成本效益分析对医院采用 TIPS 技术的影响日益重要
  • 制定标准化培训计划，提高临床医生对 TIPS 技术的熟练程度
  • 加强抗生素预防通讯协定可降低经颈静脉分流手术后的感染率

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 经颈静脉肝内门体分流术（TIPS）市场（依产品类型）

  • 配件
  • 支架
    • 裸金属支架
    • 覆膜支架

9. 经颈静脉肝内门体分流术（TIPS）市场（依手术类型）

  • 选择性
  • 紧急状况

10. 经颈静脉肝内门体分流术（TIPS）市场（依最终使用者）

  • 门诊中心
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 肝病中心
    • 放射中心

11. 经颈静脉肝内门体分流术（TIPS）市场的应用

  • 布德-加利氏症候群
  • 肝肾症候群
    • 1型（HRS-1）
    • 2 型（HRS-2）
  • 顽固性腹水
    • 利尿不适当性腹水
    • 利尿剂抗性腹水
  • 静脉曲张出血

12.美国经颈静脉肝内门体分流术（TIPS）市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 欧洲、中东和非洲经颈静脉肝内门体分流术（TIPS）市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

14. 亚太经颈静脉肝内门体分流术（TIPS）市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Boston Scientific Corporation
    • WL Gore & Associates, Inc.
    • Cook Group Incorporated
    • Becton, Dickinson and Company
    • AngioDynamics Inc.
    • Argon Medical Devices, Inc.
    • Siemens Healthineers AG
    • Merit Medical Systems, Inc.
    • Sirtex Medical Inc.

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-562E923A956A

The Transjugular Intrahepatic Portosystemic Shunt Market was valued at USD 102.60 million in 2024 and is projected to grow to USD 106.83 million in 2025, with a CAGR of 4.27%, reaching USD 131.88 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 102.60 million
Estimated Year [2025] USD 106.83 million
Forecast Year [2030] USD 131.88 million
CAGR (%) 4.27%

Pioneering the Future of Transjugular Intrahepatic Portosystemic Shunt Therapy with Unmatched Clinical and Technological Innovations

Transjugular Intrahepatic Portosystemic Shunt (TIPSS) represents a landmark interventional procedure designed to alleviate portal hypertension by creating a channel that connects the portal and systemic venous circulations within the liver. This minimally invasive approach has evolved significantly since its inception, transitioning from experimental protocols to a standard of care for managing complications such as refractory ascites, variceal bleeding, Budd-Chiari syndrome, and hepatorenal syndrome. Over the years, continuous improvements in stent design, imaging guidance, and procedural techniques have enhanced both the safety profile and clinical efficacy of TIPSS, driving its adoption across cardiovascular and hepatology specialties.

Beyond clinical performance, TIPSS has catalyzed a broader transformation in interventional radiology workflows, prompting deeper collaboration between hepatologists and radiologists. With the expansion of imaging modalities such as intravascular ultrasound and cone-beam computed tomography, physicians can now achieve unparalleled precision during stent deployment. As practitioners refine patient selection criteria in line with evolving guidelines, those involved in device development, hospital procurement, and health policy recognize that sustaining these advances will require concerted efforts in training, evidence generation, and supply chain resilience.

Navigating Transformative Advances Reshaping the Transjugular Intrahepatic Portosystemic Shunt Landscape with Precision and Efficacy

The landscape of Transjugular Intrahepatic Portosystemic Shunt therapy has entered a phase of profound transformation driven by breakthroughs in device engineering and procedural guidance. Modern covered stent technologies have substantially reduced instances of in-stent restenosis and shunt dysfunction, thereby prolonging patency and improving long-term outcomes for patients with portal hypertension. Meanwhile, refinements to bare metal stents continue to play a complementary role where cost considerations and procedural flexibility are paramount.

Moreover, the integration of real-time imaging techniques has revolutionized interventional workflows. Advanced needle guidance systems and three-dimensional reconstruction software enable clinicians to navigate complex hepatic vasculature with unprecedented accuracy. As a result, complication rates have declined and procedural durations have shortened, paving the way for broader adoption in both tertiary care centers and specialized outpatient settings.

Furthermore, clinical guidelines have adapted to reflect these technological gains, expanding the indications for TIPSS to include patients with refractory ascites and select cases of hepatorenal syndrome. In parallel, remote monitoring solutions and digital health platforms are emerging to support post-procedural surveillance, ensuring early detection of shunt dysfunction and enhancing long-term patient management.

Evaluating the Comprehensive Impact of Emerging United States Tariff Measures on Transjugular Intrahepatic Portosystemic Shunt Device Accessibility and Affordability

In 2025, newly implemented U.S. tariff measures targeting imported medical devices have brought the economics of TIPSS components into sharp focus. Levies imposed on stent imports and accessory kits have incrementally increased the landed cost of specialized grafts, balloon catheters, and dilators, thereby exerting upward pressure on hospital procurement budgets. As suppliers reassess their price structures, healthcare providers are evaluating the cost-effectiveness of alternative sourcing strategies.

Consequently, device manufacturers are accelerating efforts to localize production within domestic facilities. By establishing U.S.-based manufacturing lines for covered stent materials and accessory assemblies, leading vendors are striving to mitigate tariff exposure and stabilize pricing. This shift also aligns with broader industry initiatives supporting supply chain resilience and operational continuity.

At the same time, hospital systems are leveraging group purchasing organizations and value-based contracting models to absorb incremental cost increases without compromising patient access. In some cases, providers have renegotiated service agreements to bundle TIPSS procedural costs with downstream imaging follow-up, thereby preserving overall reimbursement margins. Looking ahead, tighter collaboration between policy makers and industry stakeholders may be necessary to ensure that tariff policies support both innovation incentives and patient affordability.

Unveiling Critical Segmentation Perspectives That Illuminate Diverse Pathways in Transjugular Intrahepatic Portosystemic Shunt Market Analysis and Adoption Dynamics

An in-depth examination of product type segmentation reveals that stents have long dominated clinical preference over accessories, with a pronounced shift toward covered designs due to their superior performance in reducing shunt dysfunction. Within the covered stent category, manufacturers are differentiating through proprietary graft coatings and hybrid metal alloys aimed at balancing flexibility with radial strength. Meanwhile, accessories such as balloon dilators and guide sheaths continue to evolve, incorporating low-friction polymers and enhanced profile designs to streamline device delivery.

Turning to procedural segmentation, elective TIPSS placements account for a significant proportion of cases, driven by scheduled interventions for refractory ascites and variceal bleeding prevention. In contrast, emergency procedures are reserved for acute hemorrhagic events, where rapid access to specialized equipment and multidisciplinary coordination becomes critical. As a result, service providers are optimizing inventory allocation and on-call staffing to ensure readiness across both elective and emergent care pathways.

Insights into end-user dynamics show that hospitals remain the cornerstone of TIPSS delivery, with private institutions often pioneering new techniques and public hospitals extending access to underserved populations. Ambulatory centers are steadily expanding their role in lower-risk procedures, benefiting from streamlined reimbursement and shorter patient stays. Specialty clinics, particularly hepatology centers and radiology centers, are also carving out niche capabilities by offering integrated pre- and post-procedural care protocols that improve long-term patient monitoring and reduce readmission rates.

Application segmentation underscores the diverse clinical scenarios in which TIPSS provides therapeutic benefit. Management of Budd-Chiari syndrome and variceal bleeding continues to be a core indication, while refractory ascites cases-whether diuretic ineligible or diuretic resistant-are driving incremental adoption. Furthermore, the nuanced treatment of hepatorenal syndrome, spanning Type 1 and Type 2 presentations, is gaining traction as evidence mounts supporting early intervention. These varied applications collectively shape a dynamic market landscape in which device developers and care providers must tailor solutions to meet evolving clinical needs.

Deciphering Regional Dynamics and Adoption Drivers Influencing Transjugular Intrahepatic Portosystemic Shunt Utilization Across Americas EMEA and Asia-Pacific

Regional considerations profoundly influence the uptake and evolution of Transjugular Intrahepatic Portosystemic Shunt therapy. In North and South America, robust reimbursement frameworks and high healthcare expenditure create an environment conducive to the rapid integration of novel stent technologies. Centers of excellence in metropolitan areas spearhead clinical trials, while rural and community hospitals adopt scalable procedural platforms to broaden patient access. Across Europe, Middle East & Africa, variations in regulatory pathways and reimbursement schemes necessitate strategic alliances between device makers and regional distributors. Western Europe often serves as a bellwether for practice patterns, while emerging markets in the Middle East and Africa demonstrate growing interest in interventional radiology investments. Many governments are launching training initiatives and public-private partnerships to build local expertise and infrastructure.

Alternatively, the Asia-Pacific landscape features a dual trend of mature markets such as Japan and Australia embracing incremental innovations, and rapidly developing nations in Southeast Asia investing in capacity building. Rising incidences of liver disease, coupled with expanding healthcare coverage, are prompting hospitals and specialty clinics to incorporate TIPSS into their therapeutic portfolios. Moreover, regional consortiums are driving guidelines alignment, fostering consistency in patient selection and procedural protocols across borders.

Taken together, these diverse regional dynamics underscore the importance of a tailored approach to market entry, where local regulatory nuance, reimbursement environments, and clinical training frameworks converge to shape long-term adoption trajectories.

Highlighting Strategic Innovations, Collaborations, and Competitive Maneuvers by Leading Transjugular Intrahepatic Portosystemic Shunt Market Participants in 2025

Leading stakeholders in the Transjugular Intrahepatic Portosystemic Shunt market are deploying a range of strategic initiatives to consolidate their competitive positions. Established medical device conglomerates have invested heavily in research partnerships and clinical collaborations to refine graft biomaterials and delivery systems. These alliances not only accelerate the translation of laboratory findings into commercial offerings but also strengthen relationships with key opinion leaders who guide procedural standardization.

At the same time, agile innovators and start-ups are challenging the status quo with modular stent architectures and disposable accessory platforms designed to reduce inventory overhead. Several emerging players have secured breakthrough device designations, leveraging faster regulatory pathways in multiple regions. Furthermore, co-development agreements between global device manufacturers and local producers are on the rise, enabling tailored solutions that address specific market requirements such as cost containment and clinician preferences.

In addition, strategic acquisitions and licensing deals are enabling key participants to expand their intellectual property portfolios and bolster end-to-end service capabilities. As a result, integrated service models that combine device provision with advanced imaging support and procedural training are becoming a differentiator in high-growth markets. Collectively, these corporate maneuvers are reshaping the competitive landscape, heightening the importance of agility, customer engagement, and continuous innovation.

Implementing Actionable Strategic Directives to Amplify Clinical Efficacy and Market Penetration for Transjugular Intrahepatic Portosystemic Shunt Solutions

To capitalize on emerging opportunities and address operational challenges in the TIPSS domain, industry leaders should prioritize targeted investments in clinician education and procedural simulation programs. By fostering proficiency in advanced stent deployment techniques and imaging integration, medical centers can reduce complication rates and improve patient outcomes. Additionally, forging collaborative partnerships with hepatology and radiology societies will drive consensus on best practices, facilitating broader adoption across diverse care settings.

Another critical recommendation involves strengthening supply chain resilience through localization of key manufacturing processes. Establishing regional production hubs for graft materials and accessories not only mitigates the impact of international tariff fluctuations but also shortens lead times and supports emergency procedural readiness. Parallel to manufacturing strategies, device suppliers should engage with payers and health authorities to demonstrate the value proposition of TIPSS in reducing hospital admissions and long-term care costs.

Finally, organizations should develop data-driven post-market surveillance frameworks to capture real-world performance metrics. Leveraging digital health platforms and remote monitoring tools will enable continuous quality improvement, inform iterative device enhancements, and substantiate reimbursement claims. Collectively, these actionable steps will empower stakeholders to navigate regulatory complexities, reinforce clinical efficacy, and secure sustainable growth in a competitive marketplace.

Employing Rigorous Mixed Methodology Frameworks to Ensure Robust and Unbiased Insights into Transjugular Intrahepatic Portosystemic Shunt Market Dynamics

This analysis leverages a rigorous mixed methodology framework characterized by the integration of primary and secondary research. Primary inputs were gathered through in-depth interviews with interventional radiologists, hepatology specialists, procurement directors, and regulatory affairs experts across multiple regions. These insights were complemented by secondary source reviews, including peer-reviewed journals, device registries, clinical trial databases, and publicly available regulatory filings.

The approach further incorporated data triangulation techniques to validate findings and reconcile disparate viewpoints. Quantitative data points on procedural volumes, device utilization trends, and reimbursement policies were cross-referenced against qualitative perspectives from key opinion leaders. Additionally, the research team conducted a comprehensive competitor landscape assessment, combining patent analytics with corporate financial disclosures to uncover strategic trajectories.

Throughout the study, adherence to stringent quality protocols ensured the elimination of bias and the maintenance of analytical integrity. Continuous peer reviews and stakeholder consultations reinforced the credibility of the conclusions, delivering a robust foundation for strategic decision-making in the Transjugular Intrahepatic Portosystemic Shunt arena.

Synthesizing Key Findings to Illuminate the Future Trajectory of Transjugular Intrahepatic Portosystemic Shunt Technologies and Clinical Applications

The intersection of clinical innovation, regulatory evolution, and supply chain adaptation underscores the dynamic nature of the Transjugular Intrahepatic Portosystemic Shunt landscape. Breakthroughs in covered stent materials, imaging-enabled delivery systems, and remote patient monitoring are collectively enhancing procedural efficacy and reshaping treatment paradigms. Simultaneously, shifting tariff structures and regional reimbursement nuances are driving stakeholders to optimize manufacturing footprints and refine market access strategies.

Looking ahead, the continued expansion of TIPSS indications, including nuanced treatment of hepatorenal syndrome and refractory ascites subtypes, points toward sustained clinical demand. The competitive environment will likely intensify as established players deepen their offerings and emerging innovators introduce next-generation platforms. Against this backdrop, a data-driven approach to real-world evidence, collaborative guideline development, and adaptive reimbursement frameworks will be essential to unlock enduring value for both patients and healthcare systems.

In summary, the trajectory of TIPSS market evolution promises to be defined by the integration of advanced technologies, strategic partnerships, and an unwavering focus on patient outcomes. Stakeholders equipped with comprehensive insights and actionable recommendations will be best positioned to navigate this complex and rapidly evolving domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising global prevalence of nonalcoholic steatohepatitis driving demand for TIPS procedures
  • 5.2. Innovation in ePTFE covered stent technology improving long-term TIPS patency rates
  • 5.3. Integration of image-guided navigation systems enhancing precision in TIPS placement
  • 5.4. Adoption of telehealth platforms for postoperative monitoring of TIPS patients in remote regions
  • 5.5. Regulatory approvals for novel biodegradable stents expanding TIPS market opportunities
  • 5.6. Rising healthcare investments in emerging markets fueling uptake of TIPS interventions
  • 5.7. Hybrid operating room platforms supporting combined TIPS and portal vein embolization procedures
  • 5.8. Growing emphasis on cost-effectiveness analyses influencing hospital adoption of TIPS technology
  • 5.9. Development of standardized training programs improving clinician proficiency in TIPS techniques
  • 5.10. Enhanced antibiotic prophylaxis protocols reducing infection rates after transjugular shunt placement

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Transjugular Intrahepatic Portosystemic Shunt Market, by Product Type

  • 8.1. Introduction
  • 8.2. Accessories
  • 8.3. Stents
    • 8.3.1. Bare Metal Stent
    • 8.3.2. Covered Stent

9. Transjugular Intrahepatic Portosystemic Shunt Market, by Procedure Type

  • 9.1. Introduction
  • 9.2. Elective
  • 9.3. Emergency

10. Transjugular Intrahepatic Portosystemic Shunt Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Centers
  • 10.3. Hospitals
    • 10.3.1. Private Hospital
    • 10.3.2. Public Hospital
  • 10.4. Specialty Clinics
    • 10.4.1. Hepatology Center
    • 10.4.2. Radiology Center

11. Transjugular Intrahepatic Portosystemic Shunt Market, by Application

  • 11.1. Introduction
  • 11.2. Budd-Chiari Syndrome
  • 11.3. Hepatorenal Syndrome
    • 11.3.1. Type 1 Hrs
    • 11.3.2. Type 2 Hrs
  • 11.4. Refractory Ascites
    • 11.4.1. Diuretic Ineligible Ascites
    • 11.4.2. Diuretic Resistant Ascites
  • 11.5. Variceal Bleeding

12. Americas Transjugular Intrahepatic Portosystemic Shunt Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Transjugular Intrahepatic Portosystemic Shunt Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Transjugular Intrahepatic Portosystemic Shunt Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Boston Scientific Corporation
    • 15.3.2. W. L. Gore & Associates, Inc.
    • 15.3.3. Cook Group Incorporated
    • 15.3.4. Becton, Dickinson and Company
    • 15.3.5. AngioDynamics Inc.
    • 15.3.6. Argon Medical Devices, Inc.
    • 15.3.7. Siemens Healthineers AG
    • 15.3.8. Merit Medical Systems, Inc.
    • 15.3.9. Sirtex Medical Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHAI
  • FIGURE 24. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHSTATISTICS
  • FIGURE 25. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHCONTACTS
  • FIGURE 26. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COVERED STENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ELECTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY ELECTIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY EMERGENCY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY RADIOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY RADIOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BUDD-CHIARI SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY BUDD-CHIARI SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 1 HRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 1 HRS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 2 HRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY TYPE 2 HRS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC INELIGIBLE ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC INELIGIBLE ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC RESISTANT ASCITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY DIURETIC RESISTANT ASCITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY VARICEAL BLEEDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY VARICEAL BLEEDING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 145. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 179. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 180. ARGENTINA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 229. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 231. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 233. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 234. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 235. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 236. GERMANY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 246. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 247. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 248. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 249. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2018-2024 (USD MILLION)
  • TABLE 252. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HEPATORENAL SYNDROME, 2025-2030 (USD MILLION)
  • TABLE 253. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2018-2024 (USD MILLION)
  • TABLE 254. FRANCE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY REFRACTORY ASCITES, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY STENTS, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY PROCEDURE TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 264. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
  • TABLE 265. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 267. RUSSIA TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT MARKET SIZE, BY APPLICATION,